Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins […]

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

Neuraltus Pharmaceuticals (Menlo Park, CA) a preclinical-stage developer of small-molecule drugs focused on Amyotropic Lateral Sclerosis and dyskinesia, closed a $17M Series A financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Knopp Neurosciences (Pittsburgh, PA) early-stage drug discovery and development company focused on amyotrophic lateral sclerosis and other neurological disorders, closed a $27M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

Link Medicine (Cambridge, MA) development-stage company focused on the treatment of several neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, closed a $40M Series C financing. Participants include Clarus Ventures and SV Life Sciences.

Knopp Neurosciences (Pittsburgh, PA) a drug discovery and development company focused on neurological disorders with a lead compound for amyotrophic lateral sclerosis closed a $10M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

  

to top of page...